WHAT IS CLAIMED IS:

1. A compound of the formula:



A

in which

R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8}alkyl; C_{1-8}alkoxy; substituted C_{1-8} alkyl wherein the substituent is halo; substituted C_{1-8} alkoxy wherein the substituent is halo; trifluoroalkyl; C_{1-8}alkylthio and substituted C_{1-8}alkylthio wherein the substituent is selected from halo, trifluoroalkyl and C_{1-8}alkoxy; C_{3-6}cycloalkyl; C_{3-8}cycloalkoxy; nitro; amino; C_{1-6}alkylamino; C_{1-8}dialkylamino; C_{4-8}cycloalkylamino; cyano; carboxy; C_{1-5}alkylcarbonyloxy; C_{1-5}alkoxycarbonyloxy; formyl; carbamoyl; phenyl; and substituted phenyl wherein the substituent is selected from halo, hydroxyl, nitro, amino and cyano;

n is 0-2;

B_2 is selected from the group consisting of hydrogen; C_{1-5}alkyl; substituted C_{1-5}alkyl wherein the substituent is halo;

B_2 may have either a *cis*- or *trans*- stereochemical orientation with respect to B_1;

Y is methylene ($-CH_2-$) or carbonyl (C=O)

L is selected from the group consisting of

C_{1-8}alkylene; C_{2-10}alkenylene; C_{2-10}alkynylene; C_{3-7}cycloalkylene;

C_{3-7}cycloalkylC_{1-4}alkylene;

arylC_{1-4}alkylene;

(N-methylene)piperidin-4-yl;



(N-methylene)piperazin-4-yl;



and

(N-methylene)piperidin-4,4-diyl;



R_2 is independently selected from the group consisting of hydrogen; C_{1-5}alkyl; substituted C_{1-5}alkyl wherein the substituent is halo;

B_1 is hydrogen;

B_1 may have either a *cis*- or *trans*- stereochemical orientation with respect to B_2;

Z is selected from the group consisting of:

phenyl;



N-sulfonamido;



N-(aryl)sulfonamido;



2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;



and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;



R_3 is selected from the group consisting of C_{1-8}alkyl; substituted C_{1-8}alkyl wherein the substituent is selected from alkoxy and halo; cycloalkyl; substituted cycloalkyl wherein the substituent is selected from C_{1-8}alkoxy and halo; naphthyl; substituted naphthyl wherein the substituent is selected from halo, nitro, amino and cyano; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl wherein the substituent is selected from halo, nitro, amino and cyano;

R_4 is independently selected from the group consisting of C_{1-8}alkyl; alkoxy; hydroxy; halo; cyano, nitro; amino and alkylamino; substituted C_{1-8}alkyl wherein the substituent is halo;

m is 0-2;

with the following provisions:

when L isC_{1-8}alkylene; C_{2-10}alkenylene; C_{2-10}alkynylene; C_{37}cycloalkylene; C_{3-7}cycloalkyleneC_{1-4}alkylene; arylC_{1-4}alkylene; (N-methylene)piperidin-4-yl;
then Z is phenyl; N-sulfonamido; N-(aryl)sulfonamido; or 2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;

when L is (N-methylene)piperazin-4-yl;
then Z is phenyl or aryl; and

when L is (N-methylene)piperidin-4,4,-diyl;
then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof.

2. A compound of Claim 1 wherein R_1 is hydrogen, alkyl, halo, alkoxy, hydroxy, nitro, amino or trifluoroalkyl;

B_2 and B_1 are hydrogen;

R_2 is hydrogen or alkyl;

Y is methylene or carbonyl;

L is alkylene, alkenylene, alkynylene, (N-methylene)piperidin-4-yl,

(N-methylene)piperazin-4-yl or (N-methylene)piperidin-4,4-diyl;

Z is phenyl, N-sulfonamido, N(aryl)sulfonamido, 2,3-dihydro-2-oxo-1H-benzimidazo-1-yl or 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

R_3 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

R_4 is alkyl, alkoxy, hydroxy, halo, cyano, nitro, amino, alkylamino or substituted alkyl;

n is 0-2;

m is 0-2;

provided that when:

L is C_{1-8}alkylene, C_{2-10}alkenylene; C_{2-10}alkynylene, C_{3-7}cycloalkylene, C_{3-7}cycloalkyleneC_{1-4}alkylene, arylC_{1-4}alkylene or (N-methylene)piperidin-4-yl, then Z is phenyl, N-sulfonamido, N-(aryl)sulfonamido or 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl;

when L is (N-methylene)piperazin-4-yl, then Z is phenyl; and

when L is (N-methylene)piperidin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

3. A compound of claim 1 selected from the group consisting of:











and



5

4. A compound of claim 1 selected from the group consisting of:



5. A compound of claim 1 selected from the group consisting of:















6. A compound of claim 1 selected from the group consisting of:



7. A compound of claim 1 selected from the group consisting of:



8. A compound of claim 1 selected from the group consisting of:













9. A compound of claim 1 selected from the group consisting of:













5

10. A compound of claim 1 selected from the group consisting of:













11. A compound of claim 1 selected from the group consisting of:













12. A compound of claim 1 selected from the group consisting of:















13. A compound of claim 1 selected from the group consisting of:



14. A compound of claim 1 selected from the group consisting of:















15. A compound of the formula:



Wherein

R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8}alkyl; C_{1-8}alkoxy; substituted C_{1-8} alkoxy; trifluoroalkyl; C_{1-8}alkylthio; C_{3-6}cycloalkyl; C_{3-8}cycloalkyloxy; nitro; amino; C_{1-6}alkylamino; C_{1-8}dialkylamino; C_{4-8}cycloalkylamino; cyano; carboxy; C_{1-5}alkylcarbonyloxy; C_{1-5}alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;

n is 0 to 2

R_3 is independently selected from the group consisting of C_{1-8}alkyl; substituted C_{1-8}alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl;

L is selected from the group consisting of
C_{1-8}alkylene; C_{2-10}alkenylene; C_{2-10}alkynylene; C_{3-7}cycloalkylene;
C_{3-7}cycloalkylC_{1-4}alkylene; arylC_{1-4}alkylene;
(N- methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

16. A compound of the formula:



wherein

R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8}alkyl; C_{1-8}alkoxy; substituted C_{1-8} alkoxy; trifluoroalkyl; C_{1-8}alkylthio; C_{3-6}cycloalkyl; C_{3-8}cycloalkyloxy; nitro; amino; C_{1-6}alkylamino; C_{1-8}dialkylamino; C_{4-8}cycloalkylamino; cyano; carboxy; C_{1-5}alkylcarbonyloxy; C_{1-5}alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;

n is 0 to 2

R_4 is independently selected from the group consisting of C_{1-8}alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino and alkylamino; substituted C_{1-8}alkyl wherein the substituent is halo;

L is selected from the group consisting of
C_{1-8}alkylene; C_{2-10}alkenylene; C_{2-10}alkynylene; C_{3-7}cycloalkylene;
C_{3-7}cycloalkylC_{1-4}alkylene; arylC_{1-4}alkylene;
(N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

17. A compound of the formula:



Wherein

R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8}alkyl; C_{1-8}alkoxy; substituted C_{1-8} alkoxy; trifluoroalkyl; C_{1-8}alkylthio; C_{3-6}cycloalkyl; C_{3-8}cycloalkyloxy; nitro; amino; C_{1-6}alkylamino; C_{1-8}dialkylamino; C_{4-8}cycloalkylamino; cyano; carboxy; C_{1-5}alkylcarbonyloxy; C_{1-5}alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;

n is 0 to 2

HX is hydrochloric acid or trifluoroacetic acid

R_3 is independently selected from the group consisting of C_{1-8}alkyl; substituted C_{1-8}alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl;

L is selected from the group consisting of C_{1-8}alkylene; C_{2-10}alkenylene; C_{2-10}alkynylene; C_{3-7}cycloalkylene; C_{3-7}cycloalkylC_{1-4}alkylene; arylC_{1-4}alkylene; (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and (N-methylene)piperidin-4,4-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

18. A compound of the formula:



wherein

R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8}alkyl; C_{1-8}alkoxy; substituted C_{1-8} alkoxy; trifluoroalkyl; C_{1-8}alkylthio; C_{3-6}cycloalkyl; C_{3-8}cycloalkyloxy; nitro; amino; C_{1-6}alkylamino; C_{1-8}dialkylamino; C_{4-8}cycloalkylamino; cyano; carboxy; C_{1-5}alkylcarbonyloxy; C_{1-5}alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;

HX is hydrochloric acid or trifluoroacetic acid

n is 0 to 2

R_4 is independently selected from the group consisting of C_{1-8}alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino and alkylamino; substituted C_{1-8}alkyl wherein the substituent is halo;

L is selected from the group consisting of
C_{1-8}alkylene; C_{2-10}alkenylene; C_{2-10}alkynylene; C_{3-7}cycloalkylene; C_{3-7}cycloalkylC_{1-4}alkylene; arylC_{1-4}alkylene; (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and (N-methylene)piperidin-4,4-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

19. A compound of Claim 15 wherein:

R_1 is hydrogen, alkyl, halo, alkoxy, hydroxy, nitro, amino or trifluoroalkyl;

B_2 and B_1 are hydrogen;

R_2 is hydrogen or alkyl;

Y is methylene or carbonyl;

L is selected from the group consisting of C_{1-8}alkylene; C_{2-10}alkenylene; C_{2-10}alkynylene; C_{3-7}cycloalkylene; C_{3-7}cycloalkylC_{1-4}alkylene; arylC_{1-4}alkylene; (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and (N-methylene)piperidin-4,4-diyl;

Z is phenyl, N-sulfonamido, N(aryl)sulfonamido, 2,3-dihydro-2-oxo-1H-benzimidazo-1-yl or 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

R_3 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

R_4 is independently selected from the group consisting of C_{1-8}alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino; alkylamino; and substituted C_{1-8}alkyl wherein the substituent is halo;

n is 0-2;

m is 0-2;

provided that when:

L is C_{1-8}alkylene, C_{2-10}alkenylene; C_{2-10}alkynylene, C_{3-7}cycloalkylene, C_{3-7}cycloalkyleneC_{1-4}alkylene, arylC_{1-4}alkylene or (N-methylene)piperidin-4-yl, then Z

is phenyl, N-sulfonamido, N-(aryl)sulfonamido or 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl;

when L is (N-methylene)piperazin-4-yl, then Z is phenyl; and when

L is (N-methylene)piperidin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

20. A method of treating disorders and diseases associated with NPY receptor subtype Y5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.

21. A pharmaceutical composition for the treatment of diseases or disorders associated with NPY Y5 receptor subtype comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition according to Claim 21 for the treatment of disorders or disease states caused by eating disorders, obesity, anorexia nervosa, bulimia nervosa, diabetes, dyspilipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disorders, pain, sexual/reproductive disorders, depression or anxiety.